BEX1

Summary

BEX1 (brain expressed X-linked 1, HGNC:1036) is a protein-coding gene on chromosome Xq22.1, encoding Protein BEX1 (Q9HBH7). Signaling adapter molecule involved in p75NTR/NGFR signaling.

Enables RNA polymerase II-specific DNA-binding transcription factor binding activity. Involved in positive regulation of DNA-binding transcription factor activity and positive regulation of transcription by RNA polymerase II. Part of transcription regulator complex.

Source: NCBI Gene 55859 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 31 total — 2 pathogenic
• MANE Select transcript: NM_018476

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1036
Approved symbol	BEX1
Name	brain expressed X-linked 1
Location	Xq22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000133169
Ensembl biotype	protein_coding
OMIM	300690
Entrez	55859

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 protein_coding

ENST00000372728, ENST00000885580, ENST00000885581, ENST00000885582, ENST00000885583, ENST00000885584, ENST00000933949, ENST00000933950, ENST00000933951, ENST00000933952, ENST00000933953, ENST00000933954, ENST00000933955, ENST00000953426

RefSeq mRNA: 1 — MANE Select: NM_018476 NM_018476

CCDS: CCDS35354

Canonical transcript exons

ENST00000372728 — 3 exons

Exon	Start	End
ENSE00001105455	103063642	103063731
ENSE00001105457	103064096	103064171
ENSE00001458479	103062651	103063279

Expression profiles

Bgee: expression breadth ubiquitous, 238 present calls, max score 99.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 139.5323 / max 7115.6011, expressed in 1095 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199979	138.8785	1094
199978	0.6538	206

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	99.96	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.90	gold quality
middle temporal gyrus	UBERON:0002771	99.89	gold quality
orbitofrontal cortex	UBERON:0004167	99.72	gold quality
primary visual cortex	UBERON:0002436	99.62	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	99.57	gold quality
superior frontal gyrus	UBERON:0002661	99.56	gold quality
prefrontal cortex	UBERON:0000451	99.54	gold quality
occipital lobe	UBERON:0002021	99.54	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.54	gold quality
frontal cortex	UBERON:0001870	99.53	gold quality
pituitary gland	UBERON:0000007	99.52	gold quality
adenohypophysis	UBERON:0002196	99.51	gold quality
hypothalamus	UBERON:0001898	99.48	gold quality
right frontal lobe	UBERON:0002810	99.48	gold quality
CA1 field of hippocampus	UBERON:0003881	99.48	gold quality
entorhinal cortex	UBERON:0002728	99.47	gold quality
cerebral cortex	UBERON:0000956	99.45	gold quality
neocortex	UBERON:0001950	99.45	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.45	gold quality
temporal lobe	UBERON:0001871	99.41	gold quality
superior vestibular nucleus	UBERON:0007227	99.41	gold quality
nucleus accumbens	UBERON:0001882	99.40	gold quality
cerebellar vermis	UBERON:0004720	99.39	gold quality
parietal lobe	UBERON:0001872	99.38	gold quality
pons	UBERON:0000988	99.37	gold quality
postcentral gyrus	UBERON:0002581	99.36	gold quality
amygdala	UBERON:0001876	99.35	gold quality
type B pancreatic cell	CL:0000169	99.34	gold quality
forebrain	UBERON:0001890	99.34	gold quality

Single-cell (SCXA)

Detected in 24 experiment(s), a significant marker in 17.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	2949.50
E-GEOD-124263	yes	2483.50
E-MTAB-8271	yes	976.11
E-MTAB-9435	yes	686.01
E-MTAB-10662	yes	539.19
E-MTAB-9906	yes	531.79
E-MTAB-8381	yes	451.43
E-HCAD-10	yes	385.92
E-HCAD-35	yes	48.19
E-HCAD-5	yes	42.99
E-MTAB-7316	yes	42.20
E-GEOD-84465	yes	23.34
E-GEOD-81547	yes	21.45
E-MTAB-5061	yes	10.75
E-HCAD-25	yes	9.61

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting BEX1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-18A-5P	99.29	71.05	806
HSA-MIR-18B-5P	99.29	71.05	806
HSA-MIR-133A-5P	99.28	69.13	941
HSA-MIR-4735-3P	99.14	69.85	777
HSA-MIR-12135	98.99	70.26	1814
HSA-MIR-6074	98.89	69.64	2187
HSA-MIR-8060	98.61	66.93	1187
HSA-MIR-299-5P	98.56	71.14	1140
HSA-MIR-5581-3P	98.55	70.31	1161
HSA-MIR-6837-3P	98.42	66.71	1149
HSA-MIR-320E	97.49	65.96	865
HSA-MIR-6872-3P	97.08	66.99	750
HSA-MIR-600	97.07	66.73	1259
HSA-MIR-10A-3P	93.57	64.43	451
HSA-MIR-662	90.64	62.72	148

Literature-anchored findings (GeneRIF, showing 15)

• This new human gene is mapped to the X chromosome and has an expression pattern of a spermatogenesis-related gene. (PMID:11989783)
• Two novel brain expressed genes, BEX1 and BEX2 are identified; they are silenced in all glioma specimens and exhibit extensive promoter hypermethylation. (PMID:16818640)
• expression of hBex1 in leukemic cells is a novel mechanism by which chemoresistance is achieved and suggests that hBex1 is a potential molecular target for the development of novel leukemia treatments (PMID:19028701)
• Silencing of BEX1 and LDOC1 by promoter hypermethylation might represent a critical event in the molecular pathogenesis of oral squamous cell carcinoma (OSCC) and the male predominance of OSCC occurrence. (PMID:23362108)
• Epigenetic inactivation of BEX1 supports its role as a candidate tumour suppressor gene in intracranial ependymoma (PMID:24333734)
• Our results revealed an interaction between BEX1 and BCL-2 and a novel mechanism of imatinib resistance mediated by the BEX1/BCL-2 pathway. (PMID:24626299)
• Bex family members play important roles in the formation of protein network hubs. (PMID:25612294)
• loss of BEX1 expression in FLT3-ITD driven AML potentiates oncogenic signaling and leads to decreased overall survival (PMID:26046670)
• BEX1 functions as an mRNA-dependent effector that augments pathology-promoting gene expression during heart failure. (PMID:29192139)
• BEX1 was downregulated in esophageal squamous cell cancer (ESCC) tissues compared to adjacent normal tissues, and low BEX1 expression was significantly associated with larger tumor volume, advanced clinical, and poor survival in patients with ESCC. (PMID:30132532)
• BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. (PMID:33745298)
• DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer. (PMID:34217777)
• BEX1 and BEX4 Induce GBM Progression through Regulation of Actin Polymerization and Activation of YAP/TAZ Signaling. (PMID:34576008)
• BEX1 mediates sorafenib resistance in hepatocellular carcinoma by regulating AKT signaling. (PMID:37209973)
• BEX1 supports the stemness of hepatoblastoma by facilitating Warburg effect in a PPARgamma/PDK1 dependent manner. (PMID:37715024)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Bex2	ENSMUSG00000042750
mus_musculus	Bex1	ENSMUSG00000050071
rattus_norvegicus	Bex2	ENSRNOG00000032729
rattus_norvegicus	LOC100912195	ENSRNOG00000033844
rattus_norvegicus		ENSRNOG00000082512

Paralogs (3): BEX2 (ENSG00000133134), BEX3 (ENSG00000166681), BEX5 (ENSG00000184515)

Protein

Protein identifiers

Protein BEX1 — Q9HBH7 (reviewed: Q9HBH7)

Alternative names: Brain-expressed X-linked protein 1

All UniProt accessions (1): Q9HBH7

UniProt curated annotations — full annotation on UniProt →

Function. Signaling adapter molecule involved in p75NTR/NGFR signaling. Plays a role in cell cycle progression and neuronal differentiation. Inhibits neuronal differentiation in response to nerve growth factor (NGF). May act as a link between the cell cycle and neurotrophic factor signaling, possibly by functioning as an upstream modulator of receptor signaling, coordinating biological responses to external signals with internal cellular states. In absence of reductive stress, acts as a pseudosubstrate for the CRL2(FEM1B) complex: associates with FEM1B via zinc, thereby preventing association between FEM1B and its substrates.

Subunit / interactions. Interacts with neurotrophin receptor p75NTR/NGFR. Interacts with OMP.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Expressed in central nervous system, with high level in pituitary, cerebellum and temporal lobe. Expressed in lung, skeletal muscle, peripheral blood leukocyte, stomach, lymph node, trachea and bone marrow. Highly expressed in acute myeloid leukemia.

Post-translational modifications. Phosphorylated. Phosphorylation of Ser-102 protects it from the proteasome. Ubiquitinated. Degraded by the proteasome.

Domain organisation. The histidine cluster (His cluster) and Cys-122 mediate zinc-binding.

Similarity. Belongs to the BEX family.

RefSeq proteins (1): NP_060946* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007623	BEX	Family
IPR021156	TF_A-like/BEX	Family

Pfam: PF04538

UniProt features (17 total): sequence variant 7, region of interest 3, sequence conflict 3, chain 1, compositionally biased region 1, binding site 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HBH7-F1	68.10	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 122

Post-translational modifications (1): 102

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 220 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, MODULE_151, LA_MEN1_TARGETS, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, BORLAK_LIVER_CANCER_EGF_UP, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM3, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, KHETCHOUMIAN_TRIM24_TARGETS_UP, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS, CAIRO_HEPATOBLASTOMA_UP, AFFAR_YY1_TARGETS_UP, PID_P75_NTR_PATHWAY

GO Biological Process (5): signal transduction (GO:0007165), nervous system development (GO:0007399), cell differentiation (GO:0030154), negative regulation of protein ubiquitination (GO:0031397), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (6): transcription coactivator binding (GO:0001223), signaling receptor binding (GO:0005102), signaling adaptor activity (GO:0035591), metal ion binding (GO:0046872), molecular function inhibitor activity (GO:0140678), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), transcription regulator complex (GO:0005667), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
system development	1
cellular developmental process	1
protein ubiquitination	1
regulation of protein ubiquitination	1
negative regulation of protein modification by small protein conjugation or removal	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
transcription coregulator binding	1
protein binding	1
protein-macromolecule adaptor activity	1
cation binding	1
molecular function regulator activity	1
binding	1
intracellular membrane-bounded organelle	1
protein-containing complex	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

848 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BEX1	LMO2	P25791	895
BEX1	LDB2	O43679	875
BEX1	LDB1	Q86U70	868
BEX1	NHLH2	Q02577	833
BEX1	CALML6	Q8TD86	748
BEX1	CALML3	P27482	748
BEX1	CALML4	Q96GE6	748
BEX1	CALML5	Q9NZT1	748
BEX1	CALM1	P02593	667
BEX1	TCEAL5	Q5H9L2	644
BEX1	TCEAL3	Q969E4	641
BEX1	OMP	P47874	583
BEX1	NGFR	P08138	516
BEX1	NGF	P01138	506
BEX1	GPRASP1	Q5JY77	493

IntAct

57 interactions, top by confidence:

A	B	Type	Score
BEX1	MDFI	psi-mi:“MI:0915”(physical association)	0.720
MDFI	BEX1	psi-mi:“MI:0915”(physical association)	0.720
TEX11	BEX1	psi-mi:“MI:0915”(physical association)	0.560
BEX1	TEX11	psi-mi:“MI:0915”(physical association)	0.560
CNOT2	BEX1	psi-mi:“MI:0915”(physical association)	0.560
CTAG1A	BEX1	psi-mi:“MI:0915”(physical association)	0.560
BEX1	PICK1	psi-mi:“MI:0915”(physical association)	0.560
KRT34	BEX1	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	BEX1	psi-mi:“MI:0915”(physical association)	0.560
MAGEA2	BEX1	psi-mi:“MI:0915”(physical association)	0.560
MEOX2	BEX1	psi-mi:“MI:0915”(physical association)	0.560
OTP	BEX1	psi-mi:“MI:0915”(physical association)	0.560
KLHL20	BEX1	psi-mi:“MI:0915”(physical association)	0.560
BEX1	CNOT2	psi-mi:“MI:0915”(physical association)	0.560
KRT31	BEX1	psi-mi:“MI:0915”(physical association)	0.560
BEX1	PTPN11	psi-mi:“MI:0915”(physical association)	0.370
GSK3B	BEX1	psi-mi:“MI:0915”(physical association)	0.370
BEX1	BAG4	psi-mi:“MI:0915”(physical association)	0.370
BCAR3	BEX1	psi-mi:“MI:0915”(physical association)	0.370
BEX1	CASP8	psi-mi:“MI:0915”(physical association)	0.370
CDH1	BEX1	psi-mi:“MI:0915”(physical association)	0.370
CHEK2	BEX1	psi-mi:“MI:0915”(physical association)	0.370
BEX1	FBXW7	psi-mi:“MI:0915”(physical association)	0.370
FGFR2	BEX1	psi-mi:“MI:0915”(physical association)	0.370
PAX2	BEX1	psi-mi:“MI:0915”(physical association)	0.370
PIK3CA	BEX1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (55): BEX1 (Two-hybrid), TEX11 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid), BEX1 (Two-hybrid)

ESM2 similar proteins: A0A1B0GVZ2, A0A2B4SJZ1, A3KGA4, B0BK70, D3ZT37, O55527, O74982, P03246, P03247, P03407, P04602, P04862, P05860, P05909, P06747, P0C569, P0C783, P12479, P14253, P15829, P16286, P19032, P20885, P22385, P22745, P24103, P31278, P69479, P69480, P69738, Q0GBX8, Q2PG52, Q2TBV0, Q38036, Q4VKV7, Q6I7R5, Q6W0C5, Q82855, Q873B8, Q89868

Diamond homologs: Q00994, Q2PG52, Q2TBV0, Q3MKP9, Q3MKQ1, Q3MKQ2, Q3ZBJ6, Q3ZBJ9, Q5H9J7, Q5R590, Q6PDU5, Q9BXY8, Q9CWT2, Q9HBH7, Q9NWD9, Q9R224, Q9WTZ8, Q9WTZ9, Q3TZW7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
AKT	“up-regulates quantity by stabilization”	BEX1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	21
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
686068	GRCh37/hg19 Xq22.1(chrX:100868897-102422345)x1	Pathogenic
691848	GRCh37/hg19 Xq22.1-22.3(chrX:102066350-105409822)x1	Pathogenic

SpliceAI

176 predictions. Top by Δscore:

Variant	Effect	Δscore
X:103063275:TACTC:T	acceptor_gain	1.0000
X:103063277:CTC:C	acceptor_gain	1.0000
X:103063278:TCC:T	acceptor_loss	1.0000
X:103063280:C:CC	acceptor_gain	1.0000
X:103063281:T:C	acceptor_loss	1.0000
X:103064090:CCTTA:C	donor_loss	1.0000
X:103064091:CTTA:C	donor_loss	1.0000
X:103064092:TTA:T	donor_loss	1.0000
X:103064093:TA:T	donor_loss	1.0000
X:103064094:A:AT	donor_loss	1.0000
X:103064095:C:A	donor_loss	1.0000
X:103063278:TC:T	acceptor_gain	0.9900
X:103063279:CC:C	acceptor_gain	0.9900
X:103063288:C:CT	acceptor_gain	0.9900
X:103063639:GACCT:G	donor_loss	0.9900
X:103063289:A:T	acceptor_gain	0.9800
X:103063650:AT:A	donor_gain	0.9800
X:103063728:AGGG:A	acceptor_gain	0.9800
X:103063651:T:TA	donor_gain	0.9700
X:103063729:GGG:G	acceptor_gain	0.9700
X:103063727:AAGGG:A	acceptor_gain	0.9600
X:103063730:GG:G	acceptor_gain	0.9600
X:103063640:A:AC	donor_gain	0.9500
X:103063641:C:CC	donor_gain	0.9500
X:103063873:T:TA	donor_gain	0.9500
X:103064094:A:AC	donor_gain	0.9500
X:103064095:C:CC	donor_gain	0.9500
X:103063665:T:TA	donor_gain	0.9400
X:103063280:C:T	acceptor_gain	0.9300
X:103063728:AGGGC:A	acceptor_loss	0.9200

AlphaMissense

847 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:103062912:A:C	F121L	0.994
X:103062912:A:T	F121L	0.994
X:103062914:A:G	F121L	0.994
X:103062901:G:T	P125H	0.962
X:103062913:A:C	F121C	0.962
X:103062913:A:G	F121S	0.961
X:103062904:A:G	M124T	0.948
X:103062948:G:C	S109R	0.945
X:103062948:G:T	S109R	0.945
X:103062950:T:G	S109R	0.945
X:103062902:G:A	P125S	0.944
X:103062901:G:C	P125R	0.940
X:103062907:A:G	L123P	0.937
X:103063000:A:G	L92P	0.937
X:103062907:A:T	L123H	0.935
X:103062911:A:G	C122R	0.932
X:103062909:G:C	C122W	0.928
X:103062902:G:T	P125T	0.927
X:103062988:A:G	L96P	0.925
X:103062963:A:C	S104R	0.924
X:103062963:A:T	S104R	0.924
X:103062965:T:G	S104R	0.924
X:103062901:G:A	P125L	0.906
X:103062952:A:T	V108D	0.899
X:103062914:A:C	F121V	0.889
X:103062914:A:T	F121I	0.866
X:103062903:C:A	M124I	0.865
X:103062903:C:G	M124I	0.865
X:103062903:C:T	M124I	0.865
X:103062907:A:C	L123R	0.854

dbSNP variants (sampled 300 via entrez): RS1002587678 (X:103065226 A>G), RS1003066320 (X:103064931 A>C,G), RS1003210186 (X:103065487 C>G), RS1005166888 (X:103063762 C>A,T), RS1005835002 (X:103064815 A>C), RS1005890355 (X:103064272 C>A,T), RS1007055909 (X:103066071 G>A,C,T), RS1007109761 (X:103065914 C>T), RS1007383678 (X:103064168 G>A,C), RS1007443501 (X:103063922 G>C), RS1007658046 (X:103062193 C>A), RS1009762775 (X:103062502 T>G), RS1010403971 (X:103065272 C>T), RS1010737624 (X:103063591 G>T), RS1011400905 (X:103065432 C>A)

Disease associations

OMIM: gene MIM:300690 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
bisphenol A	decreases expression, affects cotreatment	3
Benzo(a)pyrene	affects methylation, increases expression, decreases reaction	3
Ethanol	affects cotreatment, decreases expression, increases abundance	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
Cyclosporine	decreases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment	2
bisphenol F	affects cotreatment, decreases expression	1
dicrotophos	decreases expression	1
chlorophyllin	decreases reaction, increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	increases expression	1
nickel sulfate	decreases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
bisphenol S	decreases expression, affects cotreatment	1
NSC 689534	decreases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Carbamazepine	affects expression	1
Dexamethasone	decreases expression, affects cotreatment	1
Doxorubicin	increases expression	1
Folic Acid	decreases expression, affects cotreatment	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, decreases expression	1
Mustard Gas	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.